The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice

European Journal of Gastroenterology and Hepatology

Volumn 12, Issue 3, 2000, Pages 267-273

  Hans, Wolfgang ^a   Schölmerich, Jürgen ^a   Gross, Volker ^a   Falk, Werner ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Antibiotics; Dextran sulfate sodium; Experimental colitis; Intestinal flora

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; DEXTRAN SULFATE; METRONIDAZOLE; MYELOPEROXIDASE;

ANATOMY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL INFILTRATION; COLITIS; COLON; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GRANULOCYTE; HISTOPATHOLOGY; INTESTINE FLORA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0034025425     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200012030-00002     Document Type: Article

References (45)

1. 1 Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109:1344-1367.
2. 2 Powrie F, Leach MW. Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation. Ther Immunol 1995; 2:115-123.
3. 3 Sartor RB. Insights into the pathogenesis of inflammatory bowel diseases by new rodent models of spontaneous colitis. Inflamm Bowel Dis 1995; 1:64-75.
4. 4 Sartor RB, Rath HC, Lichtman SN, van Tol EA. Animal models of intestinal and joint inflammation. Bailliere's Clin Rheumatol 1996; 10:55-76.
5. 5 Stenson WF. Animal models of colitis. Curr Opin Gastroenterol 1995; 11:310-315.
6. 6 Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98:694-702.
7. 7 Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immuno-deficient mice. Gastroenterology 1994; 107:1643-1652.
8. 8 Ni J, Chen SF, Hollander D. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 1996; 39:234-241.
9. 9 Tessner TG, Cohn SM, Schloemann S, Stenson WF. Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology 1998; 115:874-882.
10. 10 Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, Schölmerich J, et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997; 107:353-358.
11. 11 Arai Y, Takanashi H, Kitagawa H, Okayasu I. Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice. Cytokine 1998; 10:890-896.
12. 12 Obermeier F, Kojouharoff G, Hans W, Schölmerich J, Gross V, Falk W. Interferon-gamma (IFN-γ)-and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol 1999; 116:238-245.
13. 13 Olson AD, DelBuono EA, Bitar KN, Remick DG. Antiserum to tumor necrosis factor and failure to prevent murine colitis. J Pediatr Gastroenterol Nutr 1995; 21:410-418.
14. 14 Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 1993; 38:1722-1734.
15. 15 Axelsson LG, Midtvedt T, Bylund-Fellenius AC. The role of intestinal bacteria, bacterial translocation and endotoxin in dextran sodium sulphate-induced colitis in the mouse. Microb Ecol Health Dis 1996; 9:225-237.
16. 16 Bylund-Fellenius AC, Landstrom E, Axelsson LG, Midtvedt T. Experimental colitis induced by dextran sulphate in normal and germfree mice. Microb Ecol Health Dis 1994; 7:207-215.
17. 17 Sartor RB. Role of the intestinal microflora in pathogenesis and complications. In: Inflammatory Bowel Diseases: Pathophysiology as Basis of Treatment. Schölmerich J, Kruis W, Goebell H, Hohenberger W, Gross V (editors). Dordrecht: Kluwer Academic Publishers; 1992. pp. 175-187.
18. 18 Sartor RB. Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther 1997;11(suppl 3):17-22.
19. 19 Sartor RB. The role of luminal bacteria in colitis: more than an antigenic drive. Eur J Clin Invest 1998; 28:1027-1029.
20. 20 Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75:253-261.
21. 21 Kühn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-274.
22. 22 Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez SJ, et al. The germfree slate prevents development of gu1 and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180:2359-2364.
23. 23 Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, et al;. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98:945-953.
24. 24 Rath HC, Ikeda JS, Linde HJ, Schölmerich J, Wilson KH, Sartor RB. Varying cecal bacterial loads influence colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1999; 116:310-319.
25. 25 Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66:5224-5231.
26. 26 Brandwein SL, McCabe RP, Cong Y, Waites KB, Ridwan BU, Dean PA, et al. Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J Immunol 1997; 159:44-52.
27. 27 Cong Y, Brandwein SL, McCabe RP, Lazenby A, Birkenmeier EH, Sundberg JP, et al. CD4 + T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998; 187:855-864.
28. 28 Foltz CJ, Fox JG, Cahill R, Murphy JC, Yan L, Shames B, et al. Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus. Helicobacter 1998; 3:69-78.
29. 29 Kullberg MC, Ward JM, Gorelick PL, Caspar P, Hieny S, Cheever A, et al. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12-and gamma interferon-dependent mechanism. Infect Immun 1998; 66:5157-5166.
30. 30 Li X, Fox JG, Whary MT, Yan L, Shames B, Zhao Z. SCID/NCr mice naturally infected with Helicobacter hepaticus develop progressive hepatitis, proliferative typhlitis, and colitis. Infect Immun 1998; 66:5477-5484.
31. 31 Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78:206-209.
32. 32 Onderdonk AB, Hermos JA, Dzink JL, Bartlett JG. Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology 1978; 74:521-526.
33. 33 Yamada M, Ohkusa T, Okayasu I. Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. Gut 1992; 33:1521-1527.
34. 34 Arndt H, Palitzsch KD, Grisham MB, Granger DM. Metronidazole inhibits leukocyte-endothelial cell adhesion in rat mesenteric venules. Gastroenterology 1994; 106:1271-1276.
35. 35 Videla S, Vilaseca J, Guarner F, Salas A, Treserra F, Crespo E, et al. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994; 35:1090-1097.
36. 36 Simonsen L, Hovgaard L, Mortensen PB, Brondsted H. Dextran hydrogels for colon-specific drug delivery. V. Degradation in human intestinal incubation models. Eur J Pharm Sci 1995; 3:329-337.
37. 37 Jung YJ, Lee JS, Kim HH, Kim YT, Kim YM. Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic acid. Arch Pharm Res 1998; 21:179-186.
38. 38 Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eut J Immunol 1996; 26:934-938.
39. 39 MacDonald TT. Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:445-447.
40. 40 Macpherson A, Khoo UY, Forgacs I, Philpott HJ, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38:365-375.
41. 41 Geier DL, Miner PB Jr. New therapeutic agents in the treatment of inflammatory bowel disease. Am J Med 1992; 93:199-208.
42. 42 Linn FV, Peppercorn MA. Drug therapy for inflammatory bowel disease: Part II. Am J Surg 1992; 164:178-185.
43. 43 Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108:1617-1621.
44. 44 Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32:1071-1075.
45. 45 Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1 a, spontaneously develop colitis. J Immunol 1998; 161:5733-5744.